Zacks Small Cap Has Positive View of Imunon FY2025 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Equities researchers at Zacks Small Cap increased their FY2025 earnings estimates for Imunon in a research report issued to clients and investors on Wednesday, May 14th. Zacks Small Cap analyst D. Bautz now forecasts that the company will post earnings of ($1.00) per share for the year, up from their prior forecast of ($1.02). The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share.

A number of other research firms also recently issued reports on IMNN. D. Boral Capital dropped their price objective on shares of Imunon from $29.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Imunon in a report on Wednesday, March 26th.

Imunon Trading Down 13.8%

IMNN opened at $0.48 on Friday. The company has a market cap of $7.08 million, a price-to-earnings ratio of -0.26 and a beta of 1.75. The company’s 50 day moving average is $0.88 and its 200 day moving average is $0.87. Imunon has a 12-month low of $0.46 and a 12-month high of $3.65.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.07.

Hedge Funds Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC raised its position in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.